We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Batm Advanced Communications Ld | LSE:BVC | London | Ordinary Share | IL0010849045 | ORD ILS0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.225 | -1.22% | 18.175 | 18.00 | 18.35 | 18.35 | 17.90 | 18.35 | 185,143 | 16:35:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Communications Services, Nec | 122.83M | -193k | -0.0004 | -450.00 | 78.49M |
Date | Subject | Author | Discuss |
---|---|---|---|
01/2/2021 07:07 | Can't get much more positive than the trading update :) | dds14 | |
28/1/2021 16:38 | It's an interesting discussion.There is huge growth potential in both sectors:Medical supported by Cellitron, Ador, Aldaltis and Zur Labs plus a few other companies.Celitron has a whole host of products all of which have potential to grow - ventilators, agri waste, animal protein, vaccine vials and probably more in the pipeline. Check their website.Ador produces the Nat lab kits and thePCR benches. The new Nat lab kits will take off when they launch soon as there is huge interest and they have technology included from the technology side of the business.Aldaltis focus mainly on the coronavirus test kits which will be required for another 12 months or more and they have contract with the Italian government in particular. They also have some new products including the hone test kit for covid, flu and cold.Hopefully the full accounts will provide a breakdown by division and each subsidiary, but huge potential on both sides.The technology is getting into the 5G market with NFV and Celare and Telco are benefiting from working from home and the technology required. | paulisi | |
28/1/2021 15:12 | >Doc..... Steppenwolf recorded it in the late 60's. Its a ride share company operated by BATM. | fse | |
28/1/2021 14:35 | Sandy789 I didn't say I valued the company at 110. As i said I don't understand the medical business so I'm not qualified to value the company. I get the telco stuff and it looks promising but its been like that for years. What I said was that i thought it might get to 110 based on the hype from the IC and that was purely based on the uptick in the price after the IC article. I'd be very surprised if it gets to 170 but I wish all BATM supporters good luck and hope it gets there. This is all my own opinion. I'm not trying to persuade/dissuade anyone from investing in BATM. Best that I don't comment further. | car1pet | |
28/1/2021 14:27 | Hi FSE where is this from | doccash | |
28/1/2021 14:02 | Well, you don't know what We can find Why don't you come with us little girl On a magic carpet ride Well, you don't know what We can see Why don't you tell your dreams to me Fantasy will set you free | fse | |
28/1/2021 12:41 | carpet, go read the last 8 or so articles by simon thompson. they are all on this fred. | nellyb | |
28/1/2021 12:37 | sandy, i'm not selling at this early stage of the company's growth - i think those who do will probably regret it. time will tell. | nellyb | |
28/1/2021 12:21 | My point is that i am guessing you are not turning this for 5p profit. So sell at 102 take your profit. On what basis do you value this company at 110 if you don't understand the medical business. I don't understand the business completely. However i do know that the company is operating in growth areas like 5g medical waste and testing for medical conditions. I haven't a clue what the value of the company is and i couldn't put a price on the shares. But i do know that Zvi has steered the company out of optical switches which is what attracted me in 1998 and into these growth areas making me a lot of money. I have a pretty good idea that the break up value of this company is over £400m so more than happy to hold. This is a serious business now and will follow the main market so play the footsie instead if you want to nickle and dime. | sandy789 | |
28/1/2021 11:36 | Sometimes in life when the whole market is painted red it takes balls to stay with quality share... | wizzkid211 | |
28/1/2021 11:26 | Last year's results early March for hard numbers Otherwise listen to Zvi last talk on proactive site All areas company progressing well | doccash | |
28/1/2021 11:09 | My problem with the share is the 2 very different businesses. I know nothing about the medical business so can't judge whether it is a good business or not. If the all the testing products are good why hasn't it gone gangbusters during the covid outbreak. I don't know the impact of vaccines on the business. I can see that testing will need to be required going forward but again if the products are good why aren't we seeing a pipeline of orders. I know a lot of posters are big fans of the company but I'm an investor in it to make money and I find it hard to judge the company. | car1pet | |
28/1/2021 10:15 | I don't see your point. I wanted to sell at 1.50 and missed it. I also wanted to but at 80p and missed that as well. | sandy789 | |
28/1/2021 09:39 | A bargain under £1. | leewain | |
28/1/2021 09:30 | Market makers have forced this down on no volume.For anyone panicking - hang on for the results end Feb/early Mar and the accompanying outlook statement. | paulisi | |
28/1/2021 09:27 | car1pet. No confidence in the 175p prediction from Investors chronicle then ? I am clinging on in small expectation but lots of hope......! | emeraldzebra | |
28/1/2021 08:52 | Annoying drop today I was just about to sell at 107. Most markets are down this morning coupled with yesterday's fall its over 2% down i think. I thought it might get to 110 but can't see it getting much higher. Plan to get out and watch from the sidelines | car1pet | |
26/1/2021 07:55 | Price has held up well.I suspect we should get notification of when the final results will be published within the next week.Hopefully, it will advise that results are better than anticipated. | paulisi | |
22/1/2021 18:52 | CAR1PET The Group's COVID-19 antigen test has 4+1 gene discovery capability, including the S protein, compared with a market standard of one to three gene discovery. This enables it to provide more accurate results, reducing the risk of false positives and false negatives. The Group is now offering its 4+1 kit as its standard COVID-19 antigen test, which is being delivered to several private and government customers in Europe and other geographies. BEING DELIVERED NOW IN EUROPE | wizzkid211 | |
22/1/2021 18:01 | If BATM has a product which can provide effective and accurate testing for all covid variants why are we not seeing orders going off the scale? In the UK there is much talk about lateral flow tests only being 50% accurate. If the BATM test is so good why isnt the UK buying millions of them? Patrick Vallance said today that he was talking to his counterpart in Israel about the virus. I'm puzzled that we hear from BATM about their test but no mention of the UK buying it. Am I missing something here. | car1pet | |
22/1/2021 16:56 | Not sure if this has been posted befor..... BATM Advanced Communications : confirms effectiveness of its COVID-19 test in diagnosing new strain of virus 01/19/2021 | 10:41am GMT BATM confirms effectiveness of its COVID-19 test in diagnosing new strain of virus COVID-19 tests effective in detecting the SARS-CoV-2 variant observed in the UK and elsewhere BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that its COVID-19 kit has been tested against the new SARS-CoV-2 variant - the virus that causes COVID-19 - that is being observed as rapidly spreading in the UK and elsewhere and the Group can confirm that it is effective in diagnosing this new strain. The new SARS-CoV-2 variant, referred to as SARS-CoV-2 VUI 202012/01, is defined by multiple spike (S) protein mutations as well as mutations in other genomic regions. The Group, in partnership with Tor Vergata University, continually tests its kits against any mutation that is perceived to be clinically material to ensure its kits are accurately able to detect all known variants of COVID-19. The Group's COVID-19 antigen test has 4+1 gene discovery capability, including the S protein, compared with a market standard of one to three gene discovery. This enables it to provide more accurate results, reducing the risk of false positives and false negatives. The Group is now offering its 4+1 kit as its standard COVID-19 antigen test, which is being delivered to several private and government customers in Europe and other geographies. Dr Zvi Marom, CEO of BATM, said: 'I am pleased to confirm that our COVID-19 tests are effective in accurately detecting all COVID-19 variants, including in those infected with this latest mutation. Viruses constantly change through mutation and our diagnostics platform has been built on our recognition that we must always think of the future. As a result, we were able to rapidly develop COVID-19 tests in response to the outbreak and those kits have been designed to be effective against the emergence of new variants.' Enquiries: BATM Advanced Communications Dr Zvi Marom, Chief Executive Officer +972 9866 2525 Moti Nagar, Chief Financial Officer | reeltime | |
22/1/2021 12:20 | Are vaccines the perfect solution? Read more: https://t.co/8uzLvoH | paulisi | |
21/1/2021 18:35 | Thank you Car1pet. | rawdeal1 | |
21/1/2021 17:53 | The 165k is an Uncrossing Trade (UT) this takes place at the end of the day and matches buys and sells, so its not a large single trade | car1pet | |
21/1/2021 17:06 | Showing as 165k buy | paulisi |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions